[1]

Yadav S, Couch FJ. 2019. Germline genetic testing for breast cancer risk: the past, present, and future. American Society of Clinical Oncology Educational Book 39:61−74

doi: 10.1200/EDBK_238987
[2]

Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, et al. 2014. Genetic/Familial high-risk assessment: breast and ovarian, version 1.2014. Journal of the National Comprehensive Cancer Network 12(9):1326−1338

doi: 10.6004/jnccn.2014.0127
[3]

Chiang J, Chua Z, Chan JY, Sule AA, Loke WH, et al. 2024. Strategies to improve implementation of cascade testing in hereditary cancer syndromes: a systematic review. NPJ Genomic Medicine 9(1):26

doi: 10.1038/s41525-024-00412-0
[4]

Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. 2017. National estimates of genetic testing in women with a history of breast or ovarian cancer. Journal of Clinical Oncology 35(35):3800−3806

doi: 10.1200/JCO.2017.73.6314
[5]

Golmard L, Delnatte C, Laugé A, Moncoutier V, Lefol C, et al. 2016. Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations. Oncogene 35(11):1324−1327

doi: 10.1038/onc.2015.181
[6]

Griffin NE, Buchanan TR, Smith SH, Leon AA, Meyer MF, et al. 2020. Low rates of cascade genetic testing among families with hereditary gynecologic cancer: an opportunity to improve cancer prevention. Gynecologic Oncology 156(1):140−146

doi: 10.1016/j.ygyno.2019.11.005
[7]

George R, Kovak K, Cox SL. 2015. Aligning policy to promote cascade genetic screening for prevention and early diagnosis of heritable diseases. Journal of Genetic Counseling 24:388−399

doi: 10.1007/s10897-014-9805-5
[8]

Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, et al. 2010. Expanding the criteria for BRCA mutation testing in breast cancer survivors. Journal of Clinical Oncology 28:4214−4220

doi: 10.1200/JCO.2010.28.0719
[9]

Cicin I, Bahsi T, Kose F, Kus T, Eralp Y, et al. 2026. Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician–patient survey. Scientific Reports 2026

doi: 10.1038/s41598-026-61177-3
[10]

Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, et al. 2023. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Annals of Oncology 34(1):33−47

doi: 10.1016/j.annonc.2022.10.004
[11]

Dusic EJ, Theoryn T, Wang C, Swisher EM, Bowen DJ, et al. 2022. Barriers, interventions, and recommendations: improving the genetic testing landscape. Frontiers in Digital Health 4:961128

doi: 10.3389/fdgth.2022.961128
[12]

Cohen SA, Bradbury A, Henderson V, Hoskins K, Bednar E, et al. 2019. Genetic counseling and testing in a community setting: quality, access, and efficiency. American Society of Clinical Oncology Educational Book 39:e34−e44

doi: 10.1200/EDBK_238937
[13]

Perez-Fidalgo A, Schmalfeldt B, George A, Gourley C, Pignata S, et al. 2025. Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer. International Journal of Gynecological Cancer 35(7):101863

doi: 10.1136/ijgc-2024-005497
[14]

Arun B, Couch FJ, Abraham J, Tung N, Fasching PA. 2024. BRCA-mutated breast cancer: the unmet need, challenges, and therapeutic benefits of genetic testing. British Journal of Cancer 131:1400−1414

doi: 10.1038/s41416-024-02827-z
[15]

Kostos L, Tran B, Azad AA. 2024. Combination of PARP inhibitors and androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer. Drugs 84:1093−1109

doi: 10.1007/s40265-024-02071-y
[16]

Escher M, Sappino AP. 2000. Primary care physicians' knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. Annals of Oncology 11:1131−1135

doi: 10.1023/a:1008319114278
[17]

Hann KEJ, Fraser L, Side L, Gessler S, Waller J, et al. 2017. Health care professionals' attitudes towards population-based genetic testing and risk-stratification for ovarian cancer: a cross-sectional survey. BMC Women's Health 17(1):132

doi: 10.1186/s12905-017-0488-6
[18]

Doksum T, Bernhardt BA, Holtzman NA. 2003. Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing? Genetics in Medicine 5(2):99−105

doi: 10.1097/01.GIM.0000055198.63593.32
[19]

Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, et al. 2020. Knowledge and practice regarding prostate cancer germline testing among urologists: gaps to address for optimal implementation. Cancer Treatment and Research Communications 25:100212

doi: 10.1016/j.ctarc.2020.100212
[20]

Cheng HH, Shevach JW, Castro E, Couch FJ, Domchek SM, et al. 2024. BRCA1, BRCA2, and associated cancer risks and management for male patients: a review. JAMA Oncology 10(9):1272−1281

doi: 10.1001/jamaoncol.2024.2185
[21]

Park B, Kim D, Kim J, Lee BY, Yoon J, et al. 2022. Attitudes toward risk-reducing mastectomy and risk-reducing salpingo-oophorectomy among young, unmarried, healthy women in Korea. Cancer Research and Treatment 54(2):375−382

doi: 10.4143/crt.2021.449
[22]

Chavarri-Guerra Y, Ferrigno-Guajardo A, Villarreal-Garza C, Martinez-Cannon BA, Abugattas-Saba J, et al. 2024. Uptake of risk-reducing surgeries in an international real-world cohort of Hispanic women. JCO Global Oncology 10:e2400097

doi: 10.1200/GO.24.00097
[23]

Green RF, Dotson WD, Bowen S, Kolor K, Khoury MJ. 2015. Genomics in public health: perspective from the office of public health genomics at the centers for disease control and prevention (CDC). Healthcare 3(3):830−837

doi: 10.3390/healthcare3030830
[24]

Velicer CM, Taplin S. 2001. Genetic testing for breast cancer: where are healthcare providers in the decision process? Genetics in Medicine 3(2):112−119

doi: 10.1097/00125817-200103000-00005
[25]

Frey MK, Ahsan MD, Bergeron H, Lin J, Li X, et al. 2022. Cascade testing for hereditary cancer syndromes: should we move toward direct relative contact? A systematic review and meta-analysis. Journal of Clinical Oncology 40(36):4129−4143

doi: 10.1200/JCO.22.00303
[26]

Öfverholm A, Karlsson P, Rosén A. 2024. The experience of receiving a letter from a cancer genetics clinic about risk for hereditary cancer. European Journal of Human Genetics 32(5):539−544

doi: 10.1038/s41431-024-01551-9
[27]

Henrikson NB, Scrol A, Zepp JM, Anderson ML, Blasi PR, et al. 2025. Health system-led early consent and direct contact of at-risk relatives: pilot study results. Public Health Genomics 28(1):150−162

doi: 10.1159/000545404
[28]

Varesco L, Di Tano F, Monducci J, Sciallero S, Turchetti D, et al. 2024. Cascade genetic testing in hereditary cancer: exploring the boundaries of the Italian legal framework. Familial Cancer 24(1):9

doi: 10.1007/s10689-024-00430-y
[29]

Bonini KE, Smith HS, Bonkowski ES, BerkmanBE, Jamal L. 2025. Modern family: an ethical justification for system-led contact of relatives eligible for cascade screening in the United States. Public Health Genomics 28(1):19−33

doi: 10.1159/000541301
[30]

Lindberg LJ, Wadt KAW, Therkildsen C, PetersenHV. 2024. National experiences from 30 years of provider-mediated cascade testing in Lynch syndrome families − the Danish model. Cancers 16(8):1577

doi: 10.3390/cancers16081577
[31]

Nahshon C, Lavie O, Oron G. 2023. Attitude of BRCA1/2 mutation carriers towards fertility preservation, family planning and preimplantation genetic testing for primary prevention of breast and ovarian cancer in the next generation. Journal of Assisted Reproduction and Genetics 40:2835−2842

doi: 10.1007/s10815-023-02954-1